Company intelligence / Profile preview

Hunan Weike Medical Technology

Ownership: Private
Development stage: Commercial

Overview

Weike Medical focuses on minimally invasive cardiovascular devices. Its D-shant® atrial shunt is the first such product approved in China and received FDA Breakthrough Device Designation. The DOCS VALVE® transcatheter aortic valve replacement system offers unique advantages such as treating both stenosis and regurgitation without rapid pacing or general anesthesia. Multiple products are at advanced clinical or commercial stages, with over 60 patents filed.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

none specified; strong collaborations with medical institutions and research organizations mentioned generally.

Beyond the preview

Go deeper on Hunan Weike Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Weike Medical Technology.

Explore the full profile